Treatment of high-density cells with ZEB reduced expression of surface markers (such as CD133, CD44, EpCAM) and cancer stem cell properties as well as tumorigenesis, concomitant with upregulation of genes related to apoptosis and differentiation. This evidence concerns the gene CD44 and cancer.